Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune characterization of metastatic colorectal cancer patients post reovirus administration.

BMC cancer - 18 Jun 2020

Parakrama Ruwan, Fogel Elisha, Chandy Carol, Augustine Titto, Coffey Matt, Tesfa Lydia, Goel Sanjay, Maitra Radhashree

Abstract excerpt

BACKGROUND: KRAS mutations are prevalent in 40-45% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolytic reovirus in combination with chemotherapy is examined in a phase 1 study of metastatic CRC. This study evaluates the nature of immune response by determining the cytokine expression pattern...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen-Presenting Cells
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Infusions, Intravenous

Share to Leucovorin

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Source

Open in PubMed Open full text

Identifiers

PMID: 32552875
DOI: 10.1186/s12885-020-07038-2
PMCID: PMC7301987

Genes

CD244
CD70
KRAS
TAP1
CCL5
CD4
CXCR2
EMD
IFNAR1
ITGAM
KLRD1
STAT3
VEGFA
WWOX

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune characterization of metastatic colorectal cancer patients post reovirus administration.PMID 32552875Read ↗

Immune Characterization of Metastatic Colorectal Cancer Patients Post Reovirus AdministrationSemantic proximity Read ↗

Reovirus sensitizes microsatellite stable colorectal cancer to anti-PD-1 treatment via cross-talk in innate and adaptive immune systemsSemantic proximity Read ↗

Noncoding RNA Profile in Reovirus Treated KRAS-Mutated Colorectal Cancer PatientsSemantic proximity Read ↗

Targeting high circDNA2v levels in colorectal cancer induces cellular senescence and elicits an anti-tumor secretomeSemantic proximity Read ↗

MicroRNAs immune response profile to COVID-19 vaccine boost in cancer patients under active treatmentSemantic proximity Read ↗

Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.Semantic proximity Read ↗

Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.Semantic proximity Read ↗

Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer.Semantic proximity Read ↗

Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).Semantic proximity Read ↗

Nonpathogenic E. coli engineered to surface display cytokines as a new platform for immunotherapySemantic proximity Read ↗

Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.Semantic proximity Read ↗

A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.